[HTML][HTML] Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

G Marucci, M Buccioni, D Dal Ben, C Lambertucci… - …, 2021 - Elsevier
Abstract Alzheimer's disease (AD), the most common cause of adult-onset dementia is
characterized by a progressive decline of cognitive functions accompanied by behavioral …

[HTML][HTML] The endocannabinoid system: a potential target for the treatment of various diseases

H Lowe, N Toyang, B Steele, J Bryant… - International journal of …, 2021 - mdpi.com
The Endocannabinoid System (ECS) is primarily responsible for maintaining homeostasis, a
balance in internal environment (temperature, mood, and immune system) and energy input …

Cannabidiol: pharmacology and therapeutic targets

SC Britch, S Babalonis, SL Walsh - Psychopharmacology, 2021 - Springer
Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …

Goods and bads of the endocannabinoid system as a therapeutic target: Lessons learned after 30 years

M Maccarrone, V Di Marzo, J Gertsch, U Grether… - Pharmacological …, 2023 - ASPET
The cannabis derivative marijuana is the most widely used recreational drug in the Western
world and is consumed by an estimated 83 million individuals (∼ 3% of the world …

Diversity of molecular targets and signaling pathways for CBD

DL de Almeida, LA Devi - Pharmacology research & …, 2020 - Wiley Online Library
Cannabidiol (CBD) is the second most abundant component of the Cannabis plant and is
known to have effects distinct from Δ9‐tetrahydrocannabinol (THC). Many studies that …

Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial

P McGuire, P Robson, WJ Cubala… - American Journal of …, 2018 - Am Psychiatric Assoc
Objective: Research in both animals and humans indicates that cannabidiol (CBD) has
antipsychotic properties. The authors assessed the safety and effectiveness of CBD in …

[HTML][HTML] Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain

D De Gregorio, RJ McLaughlin, L Posa… - Pain, 2019 - journals.lww.com
Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of
cannabis that interacts with the serotonin (5-HT) 1A receptor, may possess analgesic and …

[HTML][HTML] Structure of a signaling cannabinoid receptor 1-G protein complex

KK Kumar, M Shalev-Benami, MJ Robertson, H Hu… - Cell, 2019 - cell.com
Cannabis elicits its mood-enhancing and analgesic effects through the cannabinoid receptor
1 (CB1), a G protein-coupled receptor (GPCR) that signals primarily through the adenylyl …

Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials

E Chesney, D Oliver, A Green, S Sovi… - …, 2020 - nature.com
Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but
there is uncertainty about its safety. We conducted the first systematic review and meta …

[HTML][HTML] Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age

JA Crippa, FS Guimarães, AC Campos… - Frontiers in …, 2018 - frontiersin.org
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a
compound that does not produce the typical subjective effects of marijuana. Objectives: The …